Antibiotic treatment of such infections as acute otitis media (A OM) and ac ute phar yngitis has been impli cated as a maj or cause of the sprea d of bacteri al resis tance. I In many First World countries, AOM is the primary reason that childre n are prescribed antibiotics . Indeed , the clinical outco mes of patients with AOM have dramat ically cha nge d since the em ergence of bacterial resis tance to commonly used antibiotics, such as am oxicillin. The treatment of other forms of otitis-otitis extern a, AOM through tyrnp anostom y tub es (AOMT), and chro nic suppurative otiti s med ia (CSOM) -has been hindered by an increase in resistant bacteri a, albe it to a lesser ex tent than AOM .
Risk factors for multidrug resistance
In a rep ort of their multivariate analysis publish ed in 2002, Ford-Jon es et al ide ntified several risk factors that predispose pat ients to devel oping resistan ce to path ogen s: youn ger age, a lesser degree of matern al educa tion, day care atte nda nce , no history of ade no idec to my, a hi story of winter infecti on s, and am oxicilli n treat ment during the previou s 6 month s.t Th e next yea r, Darro w et al ident ified seve ral othe r factors that influenc e the etiology, prevention, and treatm ent of AO M , rec urre nt AOM , and otitis med ia with effus ion: the presence of bacte rial biofilms, a personal history of reflu x, a famil y histor y of middle ear disease, and possibl y a previous pneumoco ccal vacci natio n." To these ris k fac tors, Klein adde d recent hospitali zation and a high vo lume of antimicrobial use in the co mmunity."
Countries that restrict ant ibiotic use have relative ly low rates of resistant pneumococci (-5%), even those co untries that have very high rates of tymp an ostom y tub e insertion (e.g ., Th e Neth erlands)." Conversely, count ries with liberal over-the -coun ter antibiotic polic ies (e.g., Taiwan, Ko rea, and Southeast Asian nation s) ha ve high resistance rates (~8 0 % )."
AOM and recurrent AOM
In a lO-yea r epide miologic study of 2, 149 children in Franc e that concluded in 1997 , Geh ann o et al reported that pathogen s we re isolated from 70 % of patient s."H infiuenzae was found in 40 % of children , S pneumoniae in 31 %, and M catarrhalis in 8%. Th e incide nce of beta-lactama sesec ret ing H infi uenzae increa sed fro m 20 to 70 % ove r the period of the study, and the inci de nce ofpenicill in-resistant S pneutnoniae increa sed from 7 to 70 % . Th e finding that H inftuenzae is more co mmon than S pne unioniae in AOM has been repo rted in othe r recent ' studies , as well .?" S pneumoniae is still believed to be the most virulent patho gen in AOM and recurrent AO M. However, rece nt descriptions ofanoth er possible path ogen , Alloiococcus otitidis, in sig nifica nt numbers of children with AOM and otit is med ia w ith effusio n in Finland, Jap an , and Au stralia ha ve ge nera ted debate as to the significa nce of this new bacterium."!' If this bacter ium is found to be a path ogen in otitis medi a, then its resistance pro file to amoxi cillin/c lav ulanate, the sulfa dru gs, and ery thro myc in may have an imp act on therap y.
Ch anges in antimic robial resistan ce pattern s ha ve resulted in cha nges in the first-line man agement of AOM in different age groups (especially in ch ildren yo unger than 2 yea rs) and in those countries where the incide nce of res istant bacteri a is high :
• In the Un ited States, resis tance to trim eth oprim/sulfameth oxazole and macrolide antibiotics is increasi ng . The America n Academy of Pedi atr ics in its 2004 guide lines noted that despit e the changing prevalen ce of bact eri al path ogen s and an increase in S pn eum oniae resistanc e, amox ici llin remains the first-line antibio tic for the treatmen t of an initial episode of AOM. lin treatm ent had a higher rate of recovery of antibiotic-resista nt S pneunion iae and H influen zae fro m the nas ophary nx than did childre n with an initial episode of AOM .1 3 Ch ildren who harbor these antibiotic-resistant bacteri a easi ly transm it them to the ir family memb ers at home and to other children at day care ce nters ; transmis-
The major concern in patients with AOMT remains the secondary pathogens: P aeruginosa and S aureus, especially methicillinresistant S aureus.
sion is fac ilitated by droplet sprea d (i.e ., sneezing) from pati ent s with viral upp er respi ratory infec tio ns. Th e CD C recommends three antibio tics for trea tment of rec urre nt or persistent AOM : amoxicillin/c lav ulanate, cefuroxi me, and ceftriaxone."
• In 2003 , Huebn er et al in South Afr ica reported on patterns of antimicro bia l resistance in 173 childre n with nonresolving otitis media ." Th ey noted that 94% of 35 pneumococcal isolates were res istant to one or more antibio tics, includ ing penicill in (86 % of isolates), trimethopr irn/sulfamethoxazole (54 %), erythromycin (69 %), and c1indam ycin (57%) . Th ey reported that almost all pneumococci isolated were antibiotic-resistant, especially in young children with nonresolving otitis medi a.
Otitis extern a
Th e most extensive analysis of orga nisms invo lved in ac ute otitis extern a was reported in 2002 by Roland and Stroman.16Th ey conducted a prospective study of 2,048 ears, and isolated 2,838 bacteria, 32 yeas ts, and 17 fungi. Pseudomonas aeruginosa acco unted for 38% of the 202 bacterial species isol ated; other isolates included Staphylococcus epidermidis (9. 1%), Staphy lococcus au reus (7.8%), and Microbacter ium otitidis (6.6%); var ious other gram-positive and gram -negative bacteria acco unted for the rest. Of the S epidermidis isolates , 23 % were resistant to neo myci n, 12% were resistan t to ofloxacin, and I I % were resistant to oxacillin. P aerugi nosa resistance to f1 uoro quino lones and aminog lycosi des was uncommon. Th e authors concluded that potent broa d-s pec trum topical antibio tics are the treatm ent of choice in the diverse milieu that is acute otitis externa .
In addition, a num ber of cli nical trials have show n that the quinolones are a more effective topical therapy than ami noglycoside drops." :" With res pec t to the two most common organisms-P ae rugi nosa and S aureus-Can-16· Vol ume 86 • Suppl 1 tre ll et al reported a developing increase in resistance to neomycin and po lymyxin B but not to ofloxacin.' ?
AOMT
The natural history of tympanostomy tube otorrhea varies wit h age; often, seasonal bacteriologic differences manifest, as well. Ma nde l et al studied 246 children wit h persistent AOMT. 20 Th ey found the pathogens of AOM (i.e., S pneumoni a e, H injl uenz ae, M catarrhalis, and Strep tococcus pyogenes) in 50% of patients yo unger than 6 yea rs of age, co mpare d with only 4.4 % of children olde r than 6 yea rs at their first episode. Path ogen s that are more likely to be resis ta nt to therapy (e.g., P aeru gin osa ) were found in 43.5% of the older gro up and 20.5% of the yo unger group. Th e major conce rn in patient s with AOMT rem ains the secondary pathoge ns: P ae rug inosa and S aureus , especially methicillin-resistant S aureus (M RSA). In 2005, Coticch ia and Dohar reported that childre n wit h AOMT and isolated MRSA had received significantly more sys tem ic antibiot ic treatm ent before and after tube insertion ." CSOM Both systemic and topical thera py can be used for CSOM, whic h makes it diffic ult to determi ne whic h fo rmu lation is res ponsible for resis ta nce . In a review of eig ht art icles on CSOM published in 2004, Weber et al reported no prop ensity for the developm ent of resistant orga nisms in patients with CSOM that was treated with topical therapy." On the other hand , the use of systemic therapy for CSOM has been associated with the deve lopment of co mmunityacquired infection with resistant bacteria, such as MRSA. 23 In one recent articl e in which the authors describ ed the emergence of P aeruginosa resis tant to topical ciprofloxac in in CSOM, there was no ment ion of whether the patient s had received previous sys temic antibiotic therapy, and no pretreatment microbiologic data were ava ilable." Th ese sig nifica nt study limitation s all but invalidate the authors ' conclusion that resista nce did occ ur dur ing treatment with the oto topica l agen t.
Comparisons of topical and system ic therapy in CSO M have revealed that topical therapy is superior,":" Also , Ac uin" reviewed the literature and found only I randomized controlled com pari son 18ofa quinolone-containing ear drop and an aminoglycoside-containing drop in Australia.
In that study, the quino lone was clearly superior in clearing otorrhea in patient s with CS OM. The treatm ent period was restric ted to a maximum of 14 days to preclu de the possib ility of resistance developin g to either drop. Finally, biofilms have been identifi ed as playin g a role in CSOM. Th ese co mplex ecosystems convey antimicro bial and imm unologic resistance. With mechanical dislodgement with irrigation solutions and agents to lyse the biofilm soo n to be ava ilable, there is the possibility of facilitating the eradication of dislodged planktonic middle ear bacteria by nonototoxic drops."
Strategies to limit resistance
Ourprimary concern should be to prevent the development of resis tant microorganisms by stopping the widesprea d use of systemic antibiotics for trivial upper respiratory tract infections. When antibiotics are necessa ry, resis tance can be minimized by enco uragi ng physicians to select the appropriate agent and to prescribe the correct dosage and duration of therapy. Low et alI sugges ted some guidelines for the efficient treatment of community-acquired respiratory tract infections: ·The antibiotic's spectrum of activity should be targeted to the presumed pathoge ns.
• The antibiotic should have a high degree of clinical and bacteriologic efficacy aga inst respiratory pathogens, including resistant strains.
• The therapeutic co urse should be short and simple.
• The reg imen should be palatable and well tolerate d.
The development of new antib iotics will not necessarily resolve the resistance issue. Besides, it is better to prevent AOM and its complications than to treat them . Seve ral prevention strategies have been recommended:
• Modification of environmenta l factors -i-such as day care attendance, overcrowding, poor hygiene, and passive cigare tte smoking-may lower the incidence of AOM, especially in poorer socio eco nomic areas .
• AOM might be prevented by immunizatio n with antibacterial vaccines, such as the pneumococcal polysaccharide and polyvalent vacc ines . According to Fireman et ai, antibacterial vaccination lowered the incidence of AOM slightly (by -6%) and reduced the number of ventilation tube placements significantly (by 24%). 31 The conj ugate vaccine has caused a dimini shment of refractory AOM in the United States and a change in the order of prevalence of bacterial pathogens in AOM; H infiuenzae is now the most co mmon isolate (60%), with half or more being beta-lactamase produc ers.F Other vaccines for middle ear pathogens are under investigation.
• Antiviral vaccines also have the potential to reduce the incidence of AOM . Clements et al reported that administration with an influenza vaccine led to a 36% reduction in AOM among children attending a day care center." Belshe et al reporte d similar success with an intranasal influenza vaccine ."
• Fin ally, the incidence of AOM might be lowered by usin g novel age nts to prevent colo niza tion and the attac hme nt of bacteria to dam aged middl e ear mucosa in AOM .
One of the major ways in which we can prevent antibiotic resistance in ear disease is to use short courses of high-concentration ototopical antibiotics rather than systemic antibiotics Conclusion One of the major ways in which we can prevent antibiotic resistance in ear disease is to use shor t courses of highconcentration ototopical antibiotics rather than systemic antibiotics. In children, the most effec tive eardrops are the nonototoxic quinolones. The localiz ation of these drop s to the extern al ear in otitis externa and to the middle ear and mastoid in AOMT and CSOM reduces the possibility that the microflora in the nasopharynx will become altered.
